Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Re: In Brief Published: 14 May 2021 CARDIOVASCULAR RISK Apabetalone in chronic kidney disease
Based on the same original article we have all seen already:
Kalantar-Zadeh, K. et al. Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial. Clin. J. Am. Soc. Nephrol.16, 705–716 (2021)
